C4 Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de C4 Therapeutics' es Andrew Hirsch , nombrado en Sep 2020, tiene una permanencia de 3.58 años. compensación anual total es $2.60M, compuesta por 23.7% salario y 76.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.067% de las acciones de la empresa, por valor de $287.92K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 6.8 años, respectivamente.
Información clave
Andrew Hirsch
Chief Executive Officer (CEO)
US$3.8m
Compensación total
| Porcentaje del salario del CEO | 16.9% |
| Permanencia del CEO | 3.7yrs |
| Participación del CEO | 0.07% |
| Permanencia media de la dirección | 3.5yrs |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04C4 Therapeutics closes $181M capital raise
Jun 21C4 Therapeutics gets dosing underway in early-stage CFT7455 lymphoma trial
Jun 14C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy
Jun 07Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%
Jun 02C4 Therapeutics to advance CFT8919 into IND-enabling studies
May 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$4m | US$639k | -US$132m |
| Sep 30 2023 | n/a | n/a | -US$135m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$131m |
| Dec 31 2022 | US$3m | US$614k | -US$128m |
| Sep 30 2022 | n/a | n/a | -US$107m |
| Jun 30 2022 | n/a | n/a | -US$99m |
| Mar 31 2022 | n/a | n/a | -US$95m |
| Dec 31 2021 | US$952k | US$580k | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$80m |
| Jun 30 2021 | n/a | n/a | -US$82m |
| Mar 31 2021 | n/a | n/a | -US$73m |
| Dec 31 2020 | US$21m | US$168k | -US$66m |
Compensación vs. Mercado: La compensación total de Andrew($USD3.79M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.41M).
Compensación vs. Ingresos: La compensación de Andrew ha aumentado mientras la empresa no es rentable.
CEO
Andrew Hirsch (52 yo)
3.7yrs
Permanencia
US$3,790,099
Compensación
Mr. Andrew J. Hirsch, M.B.A., is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeuti...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 3.7yrs | US$3.79m | 0.067% $ 297.6k | |
| Co-Founder | no data | US$111.41k | 0.46% $ 2.0m | |
| Chief Scientific Officer | 6yrs | US$1.53m | 0.12% $ 531.0k | |
| Chief Medical Officer | less than a year | US$1.96m | sin datos | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| CFO & Treasurer | less than a year | sin datos | 0.013% $ 58.6k | |
| Chief Accounting Officer | less than a year | sin datos | 0.0022% $ 9.7k | |
| Chief Legal Officer & Corporate Secretary | 3.8yrs | US$3.38m | 0.014% $ 64.2k | |
| Chief People Officer | 3.3yrs | sin datos | 0.014% $ 64.2k | |
| Senior Vice President of Strategic Alliances & Business Development | 8.2yrs | sin datos | sin datos | |
| Senior Vice President of Chemistry | 3.3yrs | sin datos | sin datos | |
| Senior Vice President of Biological Sciences | 5.3yrs | sin datos | sin datos |
3.5yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CCCC se considera experimentado (3.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 3.6yrs | US$3.79m | 0.067% $ 297.6k | |
| Co-Founder | 8.4yrs | US$111.41k | 0.46% $ 2.0m | |
| Co-Founder & Member of Scientific Advisory Board | 7.5yrs | sin datos | sin datos | |
| Chairman & Lead Independent Director | 8.4yrs | US$157.91k | 0.71% $ 3.2m | |
| Independent Director | 3.2yrs | US$110.41k | 1.15% $ 5.1m | |
| Independent Director | 8.4yrs | US$121.91k | 0.017% $ 73.4k | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.8yrs | sin datos | sin datos | |
| Independent Director | 2.2yrs | US$126.41k | 0.0082% $ 36.6k |
6.8yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de CCCC se considera experimentada (6.8 años de antigüedad promedio).